IVEVF Articles, Inventiva SA - From 03/22/24

Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company f...

LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with emp...

Daix (France), Long Island City (New York, United States), March 13, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmace...

Inventiva has lifted the voluntary pause on screening and randomization in the NATiV3 clinical trial following the approval from the US central I...

Revenues of €17.5 million for the full year of 2023, compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-t...

       Daix (France), Long Island City (New York, United States), January 24, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stag...

Inventiva intends to use the proceeds to fund part of its ongoing pivotal NATiV3 Phase III clinical trial evaluating lanifibranor in patients wit...

The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inven...

The DMC recommended to continue the clinical trial without modification of the protocol, based on the pre-planned review of safety data The safet...

Cash and cash equivalents at €43.8 million, short-term deposits at €0.03 million2, and long-term deposit at €5.0 million3 as of September 3...